PNPLA3 and metabolic dysfunction-associated steatotic liver disease: Considering these findings, we hypothesize that the additive effects of the TM6SF2 E167K and PNPLA3 I148M polymorphisms on NAFLD may be associated with upregulation of SREBP-1c and FASN expression (Figure 5).